📊 GILD Key Takeaways
Is Gilead Sciences, Inc.. (GILD) a Good Investment?
Gilead demonstrates exceptional financial health with industry-leading profitability metrics (28.9% net margin, 34.0% operating margin) and robust cash generation ($9.5B FCF). The company maintains a fortress balance sheet with strong liquidity (1.55x current ratio), excellent interest coverage (39.5x), and generates significant returns on equity (37.5%) despite moderate revenue growth of 2.4% YoY.
Gilead shows strong fundamental profitability and cash generation, with $10.02B of operating cash flow and $9.46B of free cash flow supporting resilience. Balance sheet liquidity and interest coverage are solid, but revenue growth is modest and net income was flat year over year, which suggests growth quality is steady rather than accelerating. The very large EPS jump relative to flat net income also raises the possibility of non-operating or one-time effects, so the core earnings trend should be watched closely.
Why Buy Gilead Sciences, Inc.. Stock? GILD Key Strengths
- Exceptional profitability with 28.9% net margin and 34.0% operating margin, demonstrating pricing power and operational efficiency
- Strong free cash flow generation of $9.5B (32.1% FCF margin) provides substantial capital for R&D, dividends, and strategic investments
- Fortress balance sheet with $7.6B cash, excellent interest coverage ratio of 39.5x, and manageable debt-to-equity ratio of 1.10x
- Superior returns on equity (37.5%) and return on assets (14.4%) indicate efficient capital deployment
- Solid liquidity position with 1.55x current ratio and 1.40x quick ratio provides financial flexibility
- Strong operating profitability and cash generation, with 34.0% operating margin and 32.1% free cash flow margin
- Healthy financial flexibility, including $7.56B in cash, 1.55x current ratio, and 39.5x interest coverage
- High returns on capital base, with 37.5% ROE and 14.4% ROA indicating efficient earnings generation
GILD Stock Risks: Gilead Sciences, Inc.. Investment Risks
- Revenue growth of only 2.4% YoY suggests maturation in core product portfolio and potential patent cliff exposure
- Significant long-term debt of $24.9B (1.10x equity) limits financial flexibility for major acquisitions or downturns, though well-managed by cash flows
- Pharmaceutical industry faces regulatory pressures, pricing scrutiny, and R&D pipeline risk that could impact future growth
- Extreme EPS growth of 1684.2% appears to reflect one-time items or restructuring rather than operational improvement, warranting investigation
- Top-line growth remains limited at 2.4% year over year, while net income was flat, pointing to slower fundamental growth
- Leverage is meaningful, with $24.94B in long-term debt and debt/equity of 1.10x
- Reported EPS growth far exceeded net income growth, which may indicate earnings quality distortion from non-recurring items or capital structure effects
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution to address modest 2.4% YoY growth
- Free cash flow sustainability and allocation strategy (R&D investment, M&A, shareholder returns)
- Gross margin trend and product mix evolution as legacy products face potential patent expirations
- Debt reduction progress relative to strong operating cash flow generation
- Product-level revenue growth and total revenue acceleration
- Net income growth and free cash flow consistency
Gilead Sciences, Inc.. (GILD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 32.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
GILD Profit Margin, ROE & Profitability Analysis
GILD vs Healthcare Sector: How Gilead Sciences, Inc.. Compares
How Gilead Sciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Gilead Sciences, Inc.. Stock Overvalued? GILD Valuation Analysis 2026
Based on fundamental analysis, Gilead Sciences, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Gilead Sciences, Inc.. Balance Sheet: GILD Debt, Cash & Liquidity
GILD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Gilead Sciences, Inc..'s revenue has shown modest growth of 8% over the 5-year period. The most recent EPS of $4.50 reflects profitable operations.
GILD Revenue Growth, EPS Growth & YoY Performance
GILD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.5B | $1.3B | $1.00 |
| Q2 2025 | $7.0B | $1.6B | $1.29 |
| Q1 2025 | $6.7B | $1.3B | $1.04 |
| Q3 2024 | $7.1B | $1.3B | $1.00 |
| Q2 2024 | $6.6B | $1.0B | $0.83 |
| Q1 2024 | $6.4B | $1.0B | $0.80 |
| Q3 2023 | $7.0B | $1.8B | $1.42 |
| Q2 2023 | $6.3B | $1.0B | $0.83 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Gilead Sciences, Inc.. Dividends, Buybacks & Capital Allocation
GILD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Gilead Sciences, Inc.. (CIK: 0000882095)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 30, 2026 | 4 | xslF345X06/wk-form4_1774907986.xml | View → |
| Mar 20, 2026 | DEF 14A | gild014721-def14a.htm | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773788187.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773785637.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773348337.xml | View → |
❓ Frequently Asked Questions about GILD
What is the AI rating for GILD?
Gilead Sciences, Inc.. (GILD) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GILD's key strengths?
Claude: Exceptional profitability with 28.9% net margin and 34.0% operating margin, demonstrating pricing power and operational efficiency. Strong free cash flow generation of $9.5B (32.1% FCF margin) provides substantial capital for R&D, dividends, and strategic investments. ChatGPT: Strong operating profitability and cash generation, with 34.0% operating margin and 32.1% free cash flow margin. Healthy financial flexibility, including $7.56B in cash, 1.55x current ratio, and 39.5x interest coverage.
What are the risks of investing in GILD?
Claude: Revenue growth of only 2.4% YoY suggests maturation in core product portfolio and potential patent cliff exposure. Significant long-term debt of $24.9B (1.10x equity) limits financial flexibility for major acquisitions or downturns, though well-managed by cash flows. ChatGPT: Top-line growth remains limited at 2.4% year over year, while net income was flat, pointing to slower fundamental growth. Leverage is meaningful, with $24.94B in long-term debt and debt/equity of 1.10x.
What is GILD's revenue and growth?
Gilead Sciences, Inc.. reported revenue of $29.4B.
Does GILD pay dividends?
Gilead Sciences, Inc.. pays dividends, with $4,003.0M distributed to shareholders in the trailing twelve months.
Where can I find GILD SEC filings?
Official SEC filings for Gilead Sciences, Inc.. (CIK: 0000882095) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GILD's EPS?
Gilead Sciences, Inc.. has a diluted EPS of $6.78.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GILD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Gilead Sciences, Inc.. has a BUY rating with 82% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is GILD stock overvalued or undervalued?
Valuation metrics for GILD: ROE of 37.5% (sector avg: 15%), net margin of 28.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy GILD stock in 2026?
Our dual AI analysis gives Gilead Sciences, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is GILD's free cash flow?
Gilead Sciences, Inc..'s operating cash flow is $10.0B, with capital expenditures of $563.0M. FCF margin is 32.1%.
How does GILD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 28.9% (avg: 12%), ROE 37.5% (avg: 15%), current ratio 1.55 (avg: 2).
Why is GILD's return on equity (ROE) so high?
Gilead Sciences, Inc.. has a return on equity of 37.5%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 28.9% net margin.